BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

859 related articles for article (PubMed ID: 15290351)

  • 1. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylases and cancer: causes and therapies.
    Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
    Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
    Yang XJ; Seto E
    Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
    Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular mechanism of HDAC inhibitors in anticancer effects.
    Bi G; Jiang G
    Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK; Marks PA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Histone-deacetylases inhibitors: from TSA to SAHA].
    Peixoto P; Lansiaux A
    Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylation of non-histone proteins modulates cellular signalling at multiple levels.
    Spange S; Wagner T; Heinzel T; Krämer OH
    Int J Biochem Cell Biol; 2009 Jan; 41(1):185-98. PubMed ID: 18804549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulation of airway inflammation.
    Adcock IM; Tsaprouni L; Bhavsar P; Ito K
    Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
    Weidle UH; Grossmann A
    Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.